These data prompted the current study to address on a functional level in mouse models whether inhibition of the CXCL16-CXCR6 pathway might be suitable to inhibit steatohepatitis and macrophage accumulation in NAFLD. Here, CXCL16 is linked to metabolic dysfunction-associated steatotic liver disease.